AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings of claims in the application:

1. (Previously Amended) A compound of the formula:



Wherein the dashed bond represents a single or double bond;

Aryl signifies a monocyclic heteroaromatic ring selected from the group consisting of thiophene, furan, pyrrole, pyridine, pryimidine, pyridazine, and pyrazine;

R^1 is H, OH, OC_{1-3}alkyl, C_{1-3}alkyl, C_{1-3}alkyl substituted optionally with OH, or OC_{1-3}alkyl;

R^2 is H, halogen, C_{1-3}alkyl, $CONR^5R^6$, $S(=O)_mC_{1-3}$alkyl, or C_{1-3}alkyl substituted optionally with OH, or OC_{1-3}alkyl; with the proviso that if Aryl is thiophene, then $R^2 \neq H$ or halo, and $R^1 \neq OH$

R^3, R^4 are independently H, C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^5, R^6 are independently H, C_{1-3}alkyl, or C_{2-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, ~~or~~ where R^5 and R^6 optionally can be joined together ~~with saturated carbon atoms~~ to form a ~~5 or 6 membered~~ pyrrolidine or piperidine ring ~~and said carbon atoms~~ which can be either unsubstituted or substituted optionally with C_{1-3}alkyl, C_{2-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^7, R^8 are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, Δ^3-piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl, or substituted on nitrogen with C_{1-4}alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl;

n is 2 to 4;

m is 0, 1 or 2

or a pharmaceutically acceptable salt or solvate thereof.

2. (Previously Amended) A compound of the formula:



Wherein the dashed bond represents a single or double bond;

Aryl signifies a fused phenyl or monocyclic heteroaromatic ring;

R^1 is H, C_{1-5}alkyl, C_{3-5}alkenyl, an aromatic ring selected from the group consisting of phenyl, thienyl, pyridyl, and imidazoyl which is either unsubstituted or substituted optionally with OH, OC_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl, halogen, or CF_3; or C_{2-5}alkyl substituted optionally with OH, OC_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl or an aromatic ring ~~such as~~ selected from the group consisting of phenyl, thienyl, pyridyl, and imidazoyl, which is either unsubstituted or substituted optionally with OH, OC_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl, halogen, CF_3, $S(=O)_2$ NR^5R^6; or C_{3-5}alkenyl substituted optionally with OH, OC_{1-3}alkyl, or $S(=O)_mC_{1-3}$alkyl;

R^2 is H, halogen, C_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl, $S(=O)_2$ NR^5R^6, or C_{1-3}alkyl substituted optionally with OH, or OC_{1-3}alkyl;

R^3 & R^4 are independently H, C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^5, R^6 are independently H, C_{1-3}alkyl, or C_{2-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, ~~or~~ where R^5 and R^6 optionally can be joined together ~~with saturated carbon atoms~~ to form a ~~5 or 6 membered~~ pyrrolidine or piperidine ring ~~and said carbon atoms~~ which can be either unsubstituted or substituted optionally with C_{1-3}alkyl, C_{2-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^7, R^8 are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, Δ^3-piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl, or substituted on nitrogen with C_{1-4}alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl;

n is 2 to 4;

m is 0, 1 or 2

or a pharmaceutically acceptable salt or solvate thereof.

3. (Withdrawn)

4. (Withdrawn)

5. (Previously Amended) A method for lowering IOP which comprises administering to a person in need thereof, a composition comprising an effective amount of a compound of the formula:



Wherein the dashed bond represents a single or double bond;
Aryl signifies a fused phenyl or monocyclic heteroaromatic ring;
R^1 is H, OH, OC_{1-3}alkyl, C_{1-3}alkyl, C_{1-3}alkyl substituted optionally with OH, or OC_{1-3}alkyl;
R^2 is H, halogen, C_{1-3}alkyl, $CONR^5R^6$, $S(=O)_mC_{1-3}alkyl^6$, or C_{1-3}alkyl substituted optionally with OH, or OC_{1-3}alkyl;
R^3, R^4 are independently H, C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;
R^5, R^6 are independently H, C_{1-3}alkyl, or C_{2-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, ~~or~~ where R^5 and R^6 optionally can be joined together ~~with saturated carbon atoms~~ to form a ~~5 or 6 membered~~ pyrrolidine or piperidine ring ~~and said carbon atoms~~ which can be either unsubstituted or substituted optionally with C_{1-3}alkyl, C_{2-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;
R^7, R^8 are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, Δ^3-piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl, or substituted on nitrogen with C_{1-4}alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl;
n is 2 to 4;
m is 0, 1 or 2

or a pharmaceutically acceptable salt or solvate-thereof.

6. (Previously Amended) A method for lowering IOP which comprises administering to a person in need thereof, a composition comprising an effective amount of a compound of the formula:



Wherein the dashed bond represents a single or double bond;
Aryl signifies a fused phenyl or monocyclic heteroaromatic ring;
R^1 is H, C_{1-5}alkyl, C_{3-5}alkenyl, an aromatic ring ~~such as~~ selected from the group consisting of phenyl, thienyl, pyridyl, and imidazoyl, which is either unsubstituted or substituted optionally with OH, OC_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl, halogen, CF_3, or $S(=O)_2 NR^5R^6$; or C_{2-5}alkyl substituted optionally with OH, OC_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl or an aromatic ring ~~such as~~ selected from the group consisting of phenyl, thienyl, pyridyl, and imidazoyl, which is either unsubstituted or substituted optionally with OH, OC_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl, halogen, CF_3, $S(=O)_2 NR^5R^6$; or C_{3-5}alkenyl substituted optionally with OH, OC_{1-3}alkyl, or $S(=O)_mC_{1-3}$alkyl;
R^2 is H, halogen, C_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl, or C_{1-3}alkyl substituted optionally with OH, or OC_{1-3}alkyl;
R^3 & R^4 are independently H, C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;
R^5, R^6 are independently H, C_{1-3}alkyl, or C_{2-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, ~~or~~ where R^5 and R^6 optionally can be joined together ~~with saturated carbon atoms~~ to form a ~~5 or 6 membered~~ pyrrolidine or piperidine ring ~~and said carbon atoms~~ which can be either unsubstituted or substituted optionally with C_{1-3}alkyl, C_{2-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;
R^7, R^8 are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, Δ^3-piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl, or substituted on nitrogen with C_{1-4}alkoxy or phenyl which can be

unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl;
n is 2 to 4;
m is 0, 1 or 2
or a pharmaceutically acceptable salt or solvate thereof.

7. (Withdrawn)

8. (Withdrawn)

9. (Previously Amended) A method for improving blood flow to the optic nerve head and the retina which comprises administering to a person in need thereof, a composition comprising an effective amount of a compound of the formula:



Wherein the dashed bond represents a single or double bond;
Aryl signifies a fused phenyl or monocyclic heteroaromatic ring;
R^1 is H, OH, OC_{1-3}alkyl, C_{1-3}alkyl, C_{1-3}alkyl substituted optionally with OH, or OC_{1-3}alkyl;
R^2 is H, halogen, C_{1-3}alkyl, $CONR^5R^6$, $S(=O)_mC_{1-3}$alkyl, or C_{1-3}alkyl substituted optionally with OH, or OC_{1-3}alkyl;
R^3, R^4 are independently H, C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;
R^5, R^6 are independently H, C_{1-3}alkyl, or C_{2-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, ~~or~~ where R^5 and R^6 optionally can be joined together ~~with saturated carbon atoms~~ to form ~~a 5 or 6 membered~~ pyrrolidine or piperidine ring ~~and said carbon atoms~~ which can be either unsubstituted or substituted optionally with C_{1-3}alkyl, C_{2-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;
R^7, R^8 are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, Δ^3-piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl, or substituted on nitrogen with C_{1-4}alkoxy or phenyl which can be

unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl;
n is 2 to 4;
m is 0, 1 or 2
or a pharmaceutically acceptable salt or solvate thereof.

10. (Previously Amended) A method for improving blood flow to the optic nerve head and the retina which comprises administering to a person in need thereof, a composition comprising an effective amount of a compound of the formula:



Wherein the dashed bond represents a single or double bond;
Aryl signifies a fused phenyl or monocyclic heteroaromatic ring;
R^1 is H, C_{1-5}alkyl, C_{3-5}alkenyl, an aromatic ring ~~such as~~ selected from the group consisting of phenyl, thienyl, pyridyl, and imidazoyl, which is either unsubstituted or substituted optionally with OH, OC_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl, halogen, CF_3, or $S(=O)_2$ NR^5R^6; or C_{2-5}alkyl substituted optionally with OH, OC_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl or an aromatic ring ~~such as~~ selected from the group consisting of phenyl, thienyl, pyridyl, and imidazoyl, which is either unsubstituted or substituted optionally with OH, OC_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl, halogen, CF_3, $S(=O)_2$ NR^5R^6; or C_{3-5}alkenyl substituted optionally with OH, OC_{1-3}alkyl, or $S(=O)_mC_{1-3}$alkyl;
R^2 is H, halogen, C_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl, or C_{1-3}alkyl substituted optionally with OH, or OC_{1-3}alkyl;
R^3 & R^4 are independently H, C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;
R^5, R^6 are independently H, C_{1-3}alkyl, or C_{2-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, ~~or~~ where R^5 and R^6 optionally can be joined ~~together with saturated carbon atoms~~ to form a ~~5 or 6 membered~~ pyrrolidine or piperidine ring ~~and said carbon atoms~~ which can be either unsubstituted or substituted optionally with C_{1-3}alkyl, C_{2-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;
R^7, R^8 are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, Δ^3-piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C_{1-}

$_3$alkyl, or C_{1-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl, or substituted on nitrogen with C_{1-4}alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl;

n is 2 to 4;

m is 0, 1 or 2

or a pharmaceutically acceptable salt or solvate thereof.

11. (Withdrawn)

12. (Withdrawn)

13. (Previously Amended) A method for treating retinal diseases selected from the group consisting of glaucoma, age related macular degeneration (ARMD), optic neuritis, ischemic disorders, diabetic retinopathy, and retinal edema which comprises administering to a person in need thereof, a composition comprising an effective amount of a compound of the formula:



Wherein the dashed bond represents a single or double bond;

Aryl signifies a fused phenyl or monocyclic heteroaromatic ring;

R^1 is H, OH, OC_{1-3}alkyl, C_{1-3}alkyl, C_{1-3}alkyl substituted optionally with OH, or OC_{1-3}alkyl;

R^2 is H, halogen, C_{1-3}alkyl, $CONR^5R^6$, $S(=O)_mC_{1-3}$alkyl, or C_{1-3}alkyl substituted optionally with OH, or OC_{1-3}alkyl;

R^3, R^4 are independently H, C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^5, R^6 are independently H, C_{1-3}alkyl, or C_{2-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, ~~or~~ where R^5 and R^6 optionally can be joined together ~~with saturated carbon atoms~~ to form a ~~5 or 6 membered~~ pyrrolidine or piperidine ring ~~and said carbon atoms~~ which can be either unsubstituted or substituted optionally with C_{1-3}alkyl, C_{2-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^7, R^8 are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, Δ^3-piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or

substituted on carbon with one or more substituents optionally selected from C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl, or substituted on nitrogen with C_{1-4}alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl;

n is 2 to 4;

m is 0, 1 or 2

or a pharmaceutically acceptable salt or solvate thereof.

14. (Previously Amended) A method for treating retinal diseases selected from the group consisting of glaucoma, age related macular degeneration (ARMD), optic neuritis, ischemic disorders, diabetic retinopathy, and retinal edema which comprises administering to a person in need thereof, a composition comprising an effective amount of a compound of the formula:



Wherein the dashed bond represents a single or double bond;

Aryl signifies a fused phenyl or monocyclic heteroaromatic ring;

R^1 is H, C_{1-5}alkyl, C_{3-5}alkenyl, an aromatic ring ~~such as~~ selected from the group coonsisting of phenyl, thienyl, pyridyl, and imidazoyl, which is either unsubstituted or substituted optionally with OH, OC_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl, halogen, CF_3, or $S(=O)_2$ NR^5R^6; or C_{2-5}alkyl substituted optionally with OH, OC_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl or an aromatic ring ~~such as~~ selected from the group consisting of phenyl, thienyl, pyridyl, and imidazoyl which is either unsubstituted or substituted optionally with OH, OC_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl, halogen, CF_3, $S(=O)_2$ NR^5R^6; or C_{3-5}alkenyl substituted optionally with OH, OC_{1-3}alkyl, or $S(=O)_mC_{1-3}$alkyl;

R^2 is H, halogen, C_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl, or C_{1-3}alkyl substituted optionally with OH, or OC_{1-3}alkyl;

R^3 & R^4 are independently H, C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^5, R^6 are independently H, C_{1-3}alkyl, or C_{2-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, ~~or~~ where R^5 and R^6 optionally can be joined together ~~with saturated carbon atoms~~ to form a pyrrolidine or piperidine ~~5 or 6 membered~~ ring ~~and said carbon atoms~~ which can be either unsubstituted or substituted optionally with C_{1-3}alkyl,

C_{2-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^7, R^8 are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, Δ^3-piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl, or substituted on nitrogen with C_{1-4}alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl;

n is 2 to 4;

m is 0, 1 or 2

or a pharmaceutically acceptable salt or solvate thereof.

15. (Withdrawn)

16. (Withdrawn)

17. (Cancelled)

18. (Cancelled)

19. (Withdrawn)

20. (Withdrawn)

21. (Cancelled)

22. (Cancelled)

23. (Withdrawn)

24. (Withdrawn)

25. (Cancelled)

26. (Cancelled)

27. (Withdrawn)

28. (Withdrawn)

29. (Withdrawn)

30. (Withdrawn)

31. (Withdrawn)

32. (Withdrawn)

33. (Withdrawn)

34. (Cancelled)

35. (Withdrawn)

36. (Withdrawn)

37. (Withdrawn)

38. (Withdrawn)

39. (Previously Amended) A method for treating persons suffering from a sleeping disorder, depression, schizophrenia, anxiety, circadian rhythm disorders, and centrally and peripherally mediated hypertension, which comprises, administering a composition comprising a pharmaceutically effective amount of a compound of the formula:



Wherein the dashed bond represents a single or double bond
Aryl signifies a fused phenyl or monocyclic heteroaromatic ring;
R^1 is H, OH, OC_{1-3}alkyl, C_{1-3}alkyl, C_{1-3}alkyl substituted optionally with OH, or OC_{1-3}alkyl;
R^2 is H, halogen, C_{1-3}alkyl, $CONR^5R^6$, $S(=O)_mC_{1-3}$alkyl, $S(=O)_2$ NR^5R^6, C_{1-3}alkyl substituted

optionally with OH, or OC_{1-3}alkyl;

R^3, R^4 are independently H, C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^5, R^6 are independently H, C_{1-3}alkyl, or C_{2-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, ~~or~~ where R^5 and R^6 optionally can be joined together ~~with saturated carbon atoms~~ to form a ~~5 or 6 membered~~ pyrrolidine or piperidine ring ~~and said carbon atoms~~ which can be either unsubstituted or substituted optionally with C_{1-3}alkyl, C_{2-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^7, R^8 are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, Δ^3-piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl, or substituted on nitrogen with C_{1-4}alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl;

n is 2 to 4;

m is 0, 1 or 2

or a pharmaceutically acceptable salt or solvate thereof.

40. (Previously Amended) A method for treating persons suffering from a sleeping disorder, depression, schizophrenia, anxiety, obsessive compulsive disorder, circadian rhythem disorders, and centrally and peripherally mediated hypertension which comprises, administering a composition comprising a pharmaceutically effective amount of a compound of the formula:



Wherein the dashed bond represents a single or double bond;

Aryl signifies a fused phenyl or monocyclic heteroaromatic ring;

R^1 is H, C_{1-5}alkyl, C_{3-5}alkenyl, an aromatic ring ~~such as~~ selected from the group consisting of phenyl, thienyl, pyridyl, and imidazoyl, which is either unsubstituted or substituted optionally with OH, OC_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl, halogen, CF_3, or $S(=O)_2$ NR^5R^6; or C_{2-5}alkyl substituted optionally with OH, OC_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl or an

aromatic ring ~~such as~~ selected from the group consisting of phenyl, thienyl, pyridyl, and imidazoyl which is either unsubstituted or substituted optionally with OH, OC_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl, halogen, CF_3, $S(=O)_2$ NR^5R^6; or C_{3-5}alkenyl substituted optionally with OH, OC_{1-3}alkyl, or $S(=O)_mC_{1-3}$alkyl;

R^2 is H, halogen, C_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl, $S(=O)_2$ NR^5R^6, or C_{1-3}alkyl substituted optionally with OH, or OC_{1-3}alkyl;

R^3 & R^4 are independently H, C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^5, R^6 are independently H, C_{1-3}alkyl, or C_{2-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, ~~or~~ where $-R^5$ and R^6 optionally can be joined together ~~with saturated carbon atoms~~ to form a pyrrolidine or piperidine ~~5 or 6 membered ring~~ and ~~said carbon atoms~~ which can be either unsubstituted or substituted optionally with C_{1-3}alkyl, C_{2-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^7, R^8 are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, Δ^3-piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl, or substituted on nitrogen with C_{1-4}alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl;

n is 2 to 4;

m is 0, 1 or 2

or a pharmaceutically acceptable salt or solvate thereof.

41. (Withdrawn)

42. (Withdrawn)

43. (Previously Amended) A pharmaceutical composition comprising a pharmaceutically effective amount of a compound of the formula:



Wherein the dashed bond represents a single or double bond;

Aryl signifies a monocyclic heteroaromatic ring selected from the group consisting of thiophene, ~~furna~~ furan, pyrrole, pyridine, pryimidine, pyridazine, and pyrazine;

R^1 is H, OH, OC_{1-3}alkyl, C_{1-3}alkyl, C_{1-3}alkyl substituted optionally with OH, or OC_{1-3}alkyl;

R^2 is H, halogen, C_{1-3}alkyl, $CONR^5R^6$, $S(=O)_mC_{1-3}$alkyl, or C_{1-3}alkyl substituted optionally with OH, or OC_{1-3}alkyl; with the proviso that if Aryl is thiophene, then $R^2 \neq H$ or halo, and $R^1 \neq OH$

R^3, R^4 are independently H, C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^5, R^6 are independently H, C_{1-3}alkyl, or C_{2-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, ~~or~~ where R^5 and R^6 optionally can be joined together ~~with saturated carbon atoms~~ to form a ~~5 or 6 membered~~ pyrrolidine or piperidine ring ~~and said carbon atoms~~ which can be either unsubstituted or substituted optionally with C_{1-3}alkyl, C_{2-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^7, R^8 are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, Δ^3-piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl, or substituted on nitrogen with C_{1-4}alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl;

n is 2 to 4;

m is 0, 1 or 2

or a pharmaceutically acceptable salt or solvate thereof in a pharmaceutically acceptable carrier.

44. (Previously Amended) A pharmaceutical composition comprising a pharmaceutically effective amount of a compound of the formula:



Wherein the dashed bond represents a single or double bond;

Aryl signifies a monocyclic heteroaromatic ring selected from the group consisting of

thiophene, furan, pyrrole, pyridine, pryimidine, pyridazine, and pyrazine;

R^1 is H, C_{1-5}alkyl, C_{3-5}alkenyl, an aromatic ring selected from the group consisting of phenyl, thienyl, pyridyl, and imidazoyl which is either unsubstituted or substituted optionally with OH, OC_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl, halogen, or CF_3; or C_{2-5}alkyl substituted optionally with OH, OC_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl or an aromatic ring ~~such as~~ selected from the group consisting of phenyl, thienyl, pyridyl, and imidazoyl, which is either unsubstituted or substituted optionally with OH, OC_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl, halogen, CF_3, $S(=O)_2$ NR^5R^6; or C_{3-5}alkenyl substituted optionally with OH, OC_{1-3}alkyl, or $S(=O)_mC_{1-3}$alkyl;

R^2 is H, halogen, C_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl, or C_{1-3}alkyl substituted optionally with OH, or OC_{1-3}alkyl;

R^3 & R^4 are independently H, C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^5, R^6 are independently H, C_{1-3}alkyl, or C_{2-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, ~~or~~ where R^5 and R^6 optionally can be joined together ~~with saturated carbon atoms~~ to form a ~~5 or 6 membered~~ pyrrolidine or piperidine ring ~~and said carbon atoms~~ which can be either unsubstituted or substituted optionally with C_{1-3}alkyl, C_{2-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^7, R^8 are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, Δ^3-piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl, or substituted on nitrogen with C_{1-4}alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl;

n is 2 to 4;

m is 0, 1 or 2

or a pharmaceutically acceptable salt or solvate thereof in a pharmaceutically acceptable carrier.

45. (Withdrawn)

46. (Withdrawn)

47. (Original) The Compound of Claim 1 selected from the group consisting of:

6-Chloro-2-[4-[4-(2*H*-benzimidazo-2-oxo-1-yl)piperidin-1-yl]butyl]-2*H*-thieno[3,2-*e*]-1,2-thiazine 1,1-dioxide;

6-Chloro-2-[4-(4-phenylpiperazin-1-yl)butyl]-2*H*-thieno[3,2-*e*]-1,2-thiazine 1,1-dioxide;

6-Chloro-2-[4-[4-(2-fluorophenyl)piperazin-1-yl]butyl]-2*H*-thieno[3,2-*e*]-1,2-thiazine 1,1-dioxide;

6-Chloro-2-[3-[4-(3-trifluoromethylphenyl)piperazin-1-yl]propyl]-2*H*-thieno[3,2-*e*]-1,2-thiazine 1,1-dioxide;

6-Chloro-2-[3-[4-(2*H*-benzimidazol-2-oxo)piperidin-1-yl]propyl]-2*H*-thieno[3,2-*e*]-1,2-thiazine 1,1-dioxide.

48. (Withdrawn)

49. (Withdrawn)